Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 3/20 | 0.34 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.33 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.33 |
| ▸ | GRM5 | P41594 | 1/20 | 0.33 |
| ▸ | HTR1A | P08908 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5090013 | 0.81 | DPP4 (0.52) | MAPTDPP4DPP8DPP7HTR1A | |
| SCHEMBL5093360 | 0.74 | DPP4 (0.52) | DPP4DPP8HTR1A | |
| SCHEMBL5089958 | 0.72 | DPP4 (0.52) | DPP4DPP8 | |
| SCHEMBL6598196 | 0.71 | MAPT (0.51) | MAPT | |
| SCHEMBL2077222 | 0.70 | MAPT (0.51) | MAPTGRM5 | |
| SCHEMBL3453428 | 0.70 | MAPT (0.48) | MAPT | |
| SCHEMBL2077223 | 0.70 | MAPT (0.55) | MAPT | |
| SCHEMBL3453472 | 0.70 | MAPT (0.44) | MAPTDPP4DPP8DPP7GRM5 | |
| SCHEMBL10294621 | 0.70 | MAPT (0.51) | MAPT | |
| SCHEMBL3452964 | 0.68 | MAPT (0.44) | MAPTGRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7465732-B2 | (2S,4S)-4-(piperazin-1-yl)pyrrolidine-2-methanone derivatives | PFIZER INC (US) | 2008-12-16 | — | — | US | disclosed |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | PFIZER INC | 2007-07-12 | — | — | US | disclosed |
| US-20070099897-A1 | Therapeutic compounds | PFIZER INC | 2007-05-03 | — | — | US | disclosed |
| US-20060079498-A1 | Therapeutic compounds | PFIZER INC | 2006-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070099897-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | MAPT 3247/4885DPP4 31/4885DPP8 404/4885 |
| US-20070161664-A1 | THERAPEUTIC COMPOUNDS | SLC5A2, SLC5A1, REN | MAPT 3247/4885DPP4 31/4885DPP8 404/4885 |
| US-20060079498-A1 | Therapeutic compounds | SLC5A2, SLC5A1, REN | MAPT 3247/4885DPP4 31/4885DPP8 404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.